Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | TP53 |
Variant | R248W |
Impact List | missense |
Protein Effect | loss of function |
Gene Variant Descriptions | TP53 R248W is a hotspot mutation that lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R248W results in decreased transactivation of Tp53 target genes, increased cell proliferation in culture, and increased tumorigenesis in mice, and leads to decreased ATM activation, resulting in increased genetic instability (PMID: 17417627, PMID: 14743206). |
Associated Drug Resistance | |
Category Variants Paths |
TP53 mutant TP53 inact mut TP53 R248W TP53 mutant TP53 exon7 TP53 R248W |
Transcript | NM_000546.5 |
gDNA | chr17:g.7674221G>A |
cDNA | c.742C>T |
Protein | p.R248W |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_000546 | chr17:g.7674221G>A | c.742C>T | p.R248W | RefSeq | GRCh38/hg38 |
NM_001126112 | chr17:g.7674221G>A | c.742C>T | p.R248W | RefSeq | GRCh38/hg38 |
NM_001126113 | chr17:g.7674221G>A | c.742C>T | p.R248W | RefSeq | GRCh38/hg38 |
NM_001126112.2 | chr17:g.7674221G>A | c.742C>T | p.R248W | RefSeq | GRCh38/hg38 |
NM_001126113.2 | chr17:g.7674221G>A | c.742C>T | p.R248W | RefSeq | GRCh38/hg38 |
NM_000546.5 | chr17:g.7674221G>A | c.742C>T | p.R248W | RefSeq | GRCh38/hg38 |
NM_001126114.2 | chr17:g.7674221G>A | c.742C>T | p.R248W | RefSeq | GRCh38/hg38 |
NM_001126114 | chr17:g.7674221G>A | c.742C>T | p.R248W | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 R248W | lung non-small cell carcinoma | sensitive | APR-246 + Cisplatin | Preclinical | Actionable | In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of non-small lung cancer cells harboring TP53 R248W in culture (PMID: 26086967). | 26086967 |
TP53 R248W | colon carcinoma | predicted - sensitive | AZ32 + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, AZ32 treatment increased sensitivity to radiotherapy in colon carcinoma cells harboring TP53 R248W compared to radiotherapy alone in culture, resulting in increased mitotic catastrophe; however, wild-type TP53 cells were more sensitive to the treatment combination than TP53 R248W mutant cells (PMID: 29769307). | 29769307 |